Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
复制标题
DOI：
10.1038/sj.bjc.6601401
复制
发表时间：
2004-01-12
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
血管生成对于肿瘤生长和转移的形成至关重要。可以区分不同类别的血管生成抑制剂，它们各自能够抑制这一复杂过程的各个步骤之一。总结了这些药物的临床研究结果。一般来说，大多数血管生成抑制剂都可以安全使用，但肿瘤消退的情况很少见。将血管生成抑制剂与细胞毒性化疗相结合可以增强抗癌活性。最近，出现了一些有关临床疗效的有希望的数据。在使用血管生成抑制剂进行临床研究时，定义生物活性至关重要，但迄今为止还没有经过验证的技术。可以想象，在不久的将来，各种类型的血管生成抑制剂将被组合起来，以试图进一步提高抗血管生成和抗癌活性。
Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes of angiogenesis inhibitors that are each able to inhibit one of the various steps of this complex process can be distinguished. Results from clinical studies with these agents are summarised. In general, it has been shown that most angiogenesis inhibitors can be safely administered, but that tumour regressions are rare. Combining angiogenesis inhibitors with cytotoxic chemotherapy can enhance anticancer activity. Recently, some promising data with regard to clinical efficacy have been presented. While performing clinical studies with angiogenesis inhibitors, defining biological activity is crucial, but thus far no validated techniques are available. It is conceivable that in the near future various classes of angiogenesis inhibitors will be combined in an attempt to further improve antiangiogenic and anticancer activity.
登录
查看更多内容
影响因子：
8.4
作者：
Eskens, FALM;Dumez, H;van Oosterom, AT
通讯作者：
van Oosterom, AT
影响因子：
45.3
作者：
Gordon, MS;Margolin, K;Adelman, DC
通讯作者：
Adelman, DC
影响因子：
45.3
作者：
Eder, JP;Supko, JG;Kufe, DW
通讯作者：
Kufe, DW
影响因子：
45.3
作者：
Galbraith, SM;Rustin, GJS;Padhani, AR
通讯作者：
Padhani, AR
影响因子：
45.3
作者：
Herbst, RS;Hess, KR;Abbruzzese, JL
通讯作者：
Abbruzzese, JL